難治性リンパ腫または進行性または難治性の非黒色腫皮膚がん患者の治療における Talimogene Laherparepvec および Nivolumab
難治性 T 細胞および NK 細胞リンパ腫、皮膚扁平上皮がん、メルケル細胞がん、およびその他のまれな皮膚腫瘍における Talimogene Laherparepvec に続く Talimogene Laherparepvec + ニボルマブの第 II 相試験
This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
調査の概要
状態
条件
- セザリー症候群
- 難治性T細胞非ホジキンリンパ腫
- メルケル細胞がん
- 未分化大細胞型リンパ腫、ALK陽性
- 乳房外パジェット病
- 再発性 T 細胞非ホジキンリンパ腫
- 再発成熟T細胞およびNK細胞非ホジキンリンパ腫
- 難治性の成熟T細胞およびNK細胞非ホジキンリンパ腫
- 難治性菌状息肉症
- 難治性未分化大細胞型リンパ腫
- 外陰扁平上皮がん
- 皮膚扁平上皮がん
- 印環細胞腺癌
- 難治性原発性皮膚T細胞非ホジキンリンパ腫
- 未分化大細胞型リンパ腫、ALK陰性
- アポクリン癌
- 指乳頭腺癌
- 内分泌ムチン産生汗腺がん
- 汗腺癌
- 悪性汗腺新生物
- 小嚢胞性付属器癌
- NK細胞リンパ腫、分類不能
- 乳頭状腺癌
- ポロ癌
- 原発性皮膚粘液癌
- 難治性メルケル細胞がん
- 難治性皮膚扁平上皮がん
- 皮膚基底細胞がん
- 皮膚基底扁平上皮がん
- 扁平上皮エクリン管癌
- 原発不明の扁平上皮がん
- 汗腺癌
- 毛髪癌
- 円筒腫から生じる癌
- スパイラ腺腫から生じる癌
- 外眼脂腺癌
- 皮膚腺様嚢胞癌
- 皮膚付属器癌
- 皮膚の角膜腫
詳細な説明
PRIMARY OBJECTIVE:
I. To determine the frequency of patients responding (response rate) to talimogene laherparepvec monotherapy.
SECONDARY OBJECTIVES:
I. To determine the local response rate to talimogene laherparepvec in injected tumors.
II. To determine the response rate to talimogene laherparepvec + nivolumab (NIVO).
III. To identify potential pre-treatment and on-treatment correlative biomarkers of local and systemic immune response.
OUTLINE:
Patients receive talimogene laherparepvec intratumorally (IT) and nivolumab intravenously (IV) over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan or positron emission tomography (PET)/CT scan on study. Patients also undergo blood sample collection and biopsies on study.
After completion of study treatment, patients are followed up every 12 weeks for 3 years.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
California
-
Los Angeles、California、アメリカ、90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles、California、アメリカ、90033
- Los Angeles General Medical Center
-
Orange、California、アメリカ、92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Pasadena、California、アメリカ、91105
- Keck Medical Center of USC Pasadena
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- UCHealth University of Colorado Hospital
-
-
Florida
-
Aventura、Florida、アメリカ、33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Coral Gables、Florida、アメリカ、33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach、Florida、アメリカ、33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami、Florida、アメリカ、33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami、Florida、アメリカ、33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation、Florida、アメリカ、33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University
-
-
Kansas
-
Fairway、Kansas、アメリカ、66205
- University of Kansas Clinical Research Center
-
Overland Park、Kansas、アメリカ、66210
- University of Kansas Cancer Center-Overland Park
-
Overland Park、Kansas、アメリカ、66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood、Kansas、アメリカ、66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、アメリカ、02114
- Massachusetts General Hospital Cancer Center
-
-
Missouri
-
City of Saint Peters、Missouri、アメリカ、63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur、Missouri、アメリカ、63141
- Siteman Cancer Center at West County Hospital
-
Kansas City、Missouri、アメリカ、64154
- University of Kansas Cancer Center - North
-
Lee's Summit、Missouri、アメリカ、64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City、Missouri、アメリカ、64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63129
- Siteman Cancer Center-South County
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- University of Nebraska Medical Center
-
-
New Hampshire
-
Lebanon、New Hampshire、アメリカ、03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New Jersey
-
New Brunswick、New Jersey、アメリカ、08903
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Buffalo、New York、アメリカ、14263
- Roswell Park Cancer Institute
-
New York、New York、アメリカ、10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599
- UNC Lineberger Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
-
Utah
-
Salt Lake City、Utah、アメリカ、84112
- Huntsman Cancer Institute/University of Utah
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Patients must have histologic or cytologic diagnosis of non-melanoma skin cancer (NMSC) or lymphomas other than B-cell lymphomas; as both of those terms are categories rather than specific diagnoses, specific guidance on eligible tumor types is provided below
-
PART I (before February 2020 amendment): Included tumor types
-
T cell and NK cell lymphomas, including, but not limited to: cutaneous T-cell lymphomas (CTCL), mycosis fungoides (MF), Sezary syndrome (SS), peripheral T-cell lymphoma (PTCL), ALK-positive and ALK-negative anaplastic large cell lymphoma (ALCL), and NK-cell lymphomas
-
Merkel cell carcinoma
-
Squamous cell carcinoma of the skin, including keratoacanthomas, vulvar squamous carcinoma, and mixed histology tumors, such as basosquamous carcinoma, and squamous cell carcinoma of unknown primary consistent with skin origin
-
Other non-melanoma skin cancers
- Basal cell carcinoma
- Malignant sweat gland tumors, including porocarcinoma, hidradenocarcinoma, spiradenocarcinoma, cylindrocarcinoma, microcystic adnexal carcinoma and related entities, squamoid eccrine ductal carcinoma, cutaneous adenoid cystic carcinoma, digital papillary adenocarcinoma, primary cutaneous mucinous carcinoma, endocrine mucin-producing sweat gland carcinoma, primary cutaneous signet ring cell carcinoma, cutaneous apocrine gland carcinoma, and extraocular sebaceous carcinoma
- Adnexal carcinoma
- Trichilemmal carcinoma
- Extramammary Paget's disease
- Any other rare tumor of the skin with approval of principle investigator (PI)
-
-
PART II (after February 2020 amendment):
- The Merkel cell carcinoma (MCC)-2 cohort will include patients with MCC
- The squamous cell carcinoma (SCC)-2 cohort will include patients with SCC
-
PART I (before February 2020 amendment): Patients with T cell and natural killer (NK) cell lymphomas must be refractory to, be intolerant of, have relapsed following, or have refused all standard life-prolonging therapies
-
PART I (before February 2020 amendment): Patients with non-melanoma skin cancers (NMSC) must have advanced or refractory tumors
- Advanced/unresectable is defined by at least 1 of the following criteria: tumors 2 cm or more, tumors considered unresectable, tumors invading deep tissues such as muscle, cartilage or bone, tumors showing perineural invasion, and/or tumors metastatic to loco-regional lymph nodes and/or distant sites
- Refractory is defined by persistent or recurrent tumor despite prior therapy consisting of at least 1 of the following: surgery, radiation therapy, intralesional therapy, topical therapy, or systemic therapy
-
PART I (before February 2020 amendment): Subjects must have at least 1 cutaneous, subcutaneous, or nodal lesion that is suitable for intralesional injection, with or without the use of ultrasound; lesions in mucosal surfaces (periocular, nasal, etc) are not eligible for injection because the area cannot be properly contained with an occlusive dressing
-
PART I (before February 2020 amendment): Subjects must have radiographically or clinically measurable disease, defined as at least one lesion that is >= 10 mm in diameter in at least 1 dimension, or an aggregate of lesions that measures >= 10 mm in diameter in at least 1 dimension
-
PART I (before February 2020 amendment): Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions
-
PART I (before February 2020 amendment): Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
PART I (before February 2020 amendment): Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
-
PART I (before February 2020 amendment): Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
-
PART I (before February 2020 amendment): Platelets >= 75 x 10^9/L
-
PART I (before February 2020 amendment): Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (patients with Gilbert's syndrome with a total bilirubin < 3.0 mg/dL)
-
PART I (before February 2020 amendment): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
-
PART I (before February 2020 amendment): Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
-
PART I (before February 2020 amendment): Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional ULN, unless the subject is on anticoagulant therapy; (if the subject is receiving anticoagulant therapy, PT, and activated PTT [aPTT] must be within therapeutic range of intended use of anticoagulants)
-
PART I (before February 2020 amendment): Talimogene laherparepvec, nivolumab and other therapeutic agents used in this trial may cause fetal harm when administered to a pregnant woman; women of child-bearing potential (WOCBP) and must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence from heterosexual intercourse) prior to study entry, during the study participation, and for 7 months after the last dose of the drug; WOCBP must have a negative serum pregnancy test within 14 days prior to randomization; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree to use adequate contraception prior to study entry, during the study participation and for 7 months after the last dose of the drug
-
PART I (before February 2020 amendment): Ability to understand and the willingness to sign a written informed consent document
-
PART II (after February 2020 amendment): Subjects in expansion cohorts MCC-2 and SCC-2 must have a diagnosis of MCC or SCC, respectively
-
PART II (after February 2020 amendment): Subjects must have refractory disease, defined as evidence of progressive disease despite prior therapy with a PD-1 or PD-L1 blocking antibody (avelumab, pembrolizumab, nivolumab, cemiplimab, etc.); progression must have occurred during PD-1 or PD-L1 directed therapy or within 6 months of the last dose of PD-1 or PD-L1 directed therapy
-
PART II (after February 2020 amendment): Subjects must have at least 1 cutaneous, subcutaneous, or nodal lesion that is suitable for intralesional injection, with or without the use of ultrasound; lesions in mucosal surfaces (periocular, nasal, etc) are not eligible for injection because the area cannot be properly contained with an occlusive dressing
-
PART II (after February 2020 amendment): Subjects must have radiographically or clinically measurable disease, defined as at least one lesion that is >= 10 mm in diameter in at least 1 dimension, or an aggregate of lesions that measures >= 10 mm in diameter in at least 1 dimension
-
PART II (after February 2020 amendment): Subjects must be able and willing to undergo serial biopsies of injected lesion(s) and, when applicable and clinically feasible, non-injected lesions
-
PART II (after February 2020 amendment): ECOG performance status =< 2 (Karnofsky >= 60%)
-
PART II (after February 2020 amendment): Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
-
PART II (after February 2020 amendment): Hemoglobin >= 9 g/dL without transfusion in the preceding 7 days
-
PART II: P (after February 2020 amendment): Platelets >= 75 x 10^9/L
-
PART II (after February 2020 amendment): Serum total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (Patients with Gilbert's Syndrome with a total bilirubin < 3.0 mg/dL.)
-
PART II (after February 2020 amendment): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
-
PART II (after February 2020 amendment): Serum creatinine =< 1.5 mg/dL OR calculated creatinine clearance (Cockcroft-Gault formula) >= 50 mL/min OR 24-hour urine creatinine clearance >= 50 mL/min
-
PART II (after February 2020 amendment): Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) =< 1.5 x institutional ULN, unless the subject is on anticoagulant therapy; (if the subject is receiving anticoagulant therapy, PT, and aPTT must be within therapeutic range of intended use of anticoagulants)
-
PART II (after February 2020 amendment): Talimogene laherparepvec, nivolumab and other therapeutic agents used in this trial may cause fetal harm when administered to a pregnant woman; women of child-bearing potential (WOCBP) and must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence from heterosexual intercourse) prior to study entry, during the study participation, and for 7 months after the last dose of the drug; WOCBP must have a negative serum pregnancy test within 14 days prior to randomization; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately; men must agree to use adequate contraception prior to study entry, during the study participation and for 7 months after the last dose of the drug
-
PART II (after February 2020 amendment): Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Excluded tumor types
- Melanoma
- Bone sarcomas
- Soft tissue sarcomas, including angiosarcoma, primary cutaneous leiomyosarcoma, dermatofibrosarcoma protuberans
- Leukemias
- Myeloid sarcoma, leukemia cutis, and chloroma
- Hodgkin's lymphoma
- B cell lymphoma
-
Patients who have had systemic therapy or radiotherapy within 3 weeks prior to the first dose of study therapy
-
Untreated central nervous system (CNS) involvement; patients with known brain metastases are eligible if they have been treated and are stable in the view of the treating investigator
-
Previous treatment with talimogene laherparepvec or other herpes virus based therapy; (prior therapy with checkpoint inhibitors and/or other immunotherapy is allowed)
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1 excepting alopecia, peripheral sensory neuropathy, and stable endocrine insufficiencies such as thyroid and adrenal insufficiency)
-
Second primary malignancy, only if it would affect the safety of the treatment or the subject's ability to complete study-related procedures
-
History or evidence of active autoimmune disease (e.g., pneumonitis, glomerulonephritis, vasculitis, or other); or history of active autoimmune disease that has required systemic treatment (i.e., use of corticosteroids, immunosuppressive drugs or biological agents used for treatment of autoimmune diseases) within 2 months of enrollment; (replacement therapy [e.g., thyroxine for hypothyroidism, insulin for diabetes or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency] is not considered a form of systemic treatment for autoimmune disease)
-
Evidence of clinically significant immunosuppression such as the following:
- Primary immunodeficiency state such as severe combined immunodeficiency disease
- Receiving systemic immunosuppressive therapy including prednisone > 10 mg per day (or equivalent), tacrolimus, everolimus, sirolimus, mycophenolate mofetil, etanercept, infliximab, etc.
- Recipients of solid organ, bone marrow, or stem cell transplants; auto transplant recipients are allowed
- Notes: Oral steroid doses =< 10 mg/day of prednisone (or equivalent) are not considered immunosuppressive and are permitted; inhaled and intraarticular corticosteroids are permitted
-
Active herpetic skin lesions or prior complications of herpetic infection (e.g., herpetic keratitis or encephalitis)
-
Viral infections requiring intermittent or chronic systemic (intravenous or oral) treatment with an antiherpetic drug (e.g., acyclovir), other than intermittent topical use
-
Other viral infections:
- Known to have acute or chronic active hepatitis B or hepatitis C infection
- Known to have human immunodeficiency virus (HIV) infection
- Prior therapy with viral-based tumor vaccine
- Received live vaccine within 28 days prior to enrollment
-
Subject who is unwilling to minimize exposure with his/her blood or other body fluids to individuals who are at higher risks for human herpesvirus 1 (HSV-1) induced complications such as immunosuppressed individuals, individuals known to have HIV infection, pregnant women, or children under the age of 1 year, during talimogene laherparepvec treatment and through 30 days after the last dose of talimogene laherparepvec
-
Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis
-
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
-
Female subject is pregnant or breast-feeding, or planning to become pregnant during study treatment and through 7 months after the last dose of treatment; female subject of childbearing potential who is unwilling to use acceptable method(s) of effective contraception during study treatment and through 7 months after the last dose of treatment; sexually active subjects and their partners unwilling to use male or female latex condom to avoid potential viral transmission during sexual contact while on treatment and within 30 days after treatment with talimogene laherparepvec
-
Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to talimogene laherparepvec or any of its components or nivolumab, or history of severe hypersensitivity reaction to any monoclonal antibody
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Treatment (talimogene laherparepvec, nivolumab)
Patients receive talimogene laherparepvec IT and nivolumab IV over 30 minutes on day 1. Cycles repeat every 21 days for cycle 1 then every 14 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients undergo, CT scan or PET/CT on study. Patients also undergo blood sample collection and biopsies on study. |
Correlative studies Undergo blood sample collection
他の名前:
Undergo CT
他の名前:
Given IV
他の名前:
Undergo tissue biopsy
他の名前:
Undergo PET/CT Given IT
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Response rate to talimogene laherparepvec alone (Part I)
時間枠:Up to 1 year
|
Will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to 1 year
|
|
Best overall response rate to talimogene laherparepvec and nivolumab combination therapy (Part II)
時間枠:Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
根治手術の頻度(切除不能病変が切除可能になる)
時間枠:最長1年
|
最長1年
|
|
|
無増悪生存
時間枠:治療開始から進行または死亡のいずれか早い方まで、1年で評価
|
治療開始から進行または死亡のいずれか早い方まで、1年で評価
|
|
|
無増悪生存
時間枠:治療開始から進行または死亡のいずれか早い方まで、2年で評価
|
治療開始から進行または死亡のいずれか早い方まで、2年で評価
|
|
|
全生存
時間枠:1年で
|
1年で
|
|
|
全生存
時間枠:2年で
|
2年で
|
|
|
Durable response rate
時間枠:Up to 1 year
|
Will be defined as complete response or partial response lasting >= 6 months. |
Up to 1 year
|
|
Response rate by cancer type
時間枠:Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Response rate of injected lesions
時間枠:Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Response rate of non-injected lesions
時間枠:Up to 1 year
|
Will be assessed by RECIST version 1.1. |
Up to 1 year
|
|
Incidence of adverse events
時間枠:Up to week 24
|
Will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. |
Up to week 24
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in herpes simplex virus (HSV) serostatus assessed in blood specimens
時間枠:Baseline to week 6
|
Will be analyzed using descriptive statistics. A test of proportions will be performed. |
Baseline to week 6
|
|
Biomarker analysis of %PD-L1, flow cytometry for HVEM, NECTIN1/2, and IDO, tryptophan and L-kynurenine, cytokine levels, Nanostring, number of non-synonymous mutations, and % T-cell receptor (TCR) clonality
時間枠:Up to 1 year
|
Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed. |
Up to 1 year
|
|
Biomarker analysis of necrosis and Nanostring
時間枠:Up to 1 year
|
Will be analyzed using descriptive statistics. Logistic regression of response rate on the variable will be performed. |
Up to 1 year
|
|
Biomarker analysis of herpes simplex virus (HSV) status, Merkel cell polyomavirus status, and PD-L1 status
時間枠:Up to 1 year
|
Will be analyzed using descriptive statistics. Test of proportions and logistic regression will be performed. |
Up to 1 year
|
協力者と研究者
捜査官
- 主任研究者:Ann (Annie) W Silk、Dana-Farber - Harvard Cancer Center LAO
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (推定)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 遺伝性疾患、先天性疾患
- 免疫系疾患
- 感染症
- ウイルス病
- 組織型別の新生物
- 新生物、腺および上皮
- 腺癌
- DNAウイルス感染症
- 皮膚疾患
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- がん
- 神経外胚葉性腫瘍
- 新生物、生殖細胞および胚
- 新生物、神経組織
- リンパ腫
- 腫瘍性症候群、遺伝性
- 神経内分泌腫瘍
- 皮膚疾患、遺伝
- 皮脂腺疾患
- 腫瘍ウイルス感染症
- 皮膚腫瘍
- 新生物、嚢胞性、粘液性、および漿液性
- ポリオーマウイルス感染症
- 新生物、管、小葉、および髄質
- 新生物、基底細胞
- がん、神経内分泌
- 先天性、遺伝性、および新生児の疾患と異常
- 皮膚および結合組織疾患
- ヘミックおよびリンパ疾患
- 皮脂腺腫瘍
- リンチ症候群Ⅱ
- 結腸直腸腫瘍、遺伝性非ポリポーシス
- リンパ腫、T細胞
- リンパ腫、大細胞、未分化
- がん、基底細胞
- がん、メルケル細胞
- がん、印環細胞
- リンパ腫、T細胞、皮膚
- 菌状息肉症
- セザリー症候群
- 腺癌、乳頭状
- パジェット病、乳房外
- がん、基底扁平上皮
- 微小嚢胞性副癌
- エクリンポロ癌
- ミュア・トーレ症候群
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 調査手法
- 臨床検査技術
- 診断技術と手順
- 診断
- 外科的処置、手術
- 細胞学的技術
- 細胞診断
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 診断技術、外科的
- ニボルマブ
- 生検
- 標本処理
- Talimogene laherparepvec
その他の研究ID番号
- NCI-2016-01804
- UM1CA186716 (米国 NIH グラント/契約)
- 10057 (その他の識別子:CTEP)
- UM1CA186709 (米国 NIH グラント/契約)
- NCI-2016-01804 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- CINJ #091701
- 10057 (その他の識別子:Dana-Farber - Harvard Cancer Center LAO)
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。